Patents by Inventor Howard A. Rockman

Howard A. Rockman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bisphosphonate compositions and methods for treating and\or reducing cardiac dysfunction
    Patent number: 9949992
    Abstract: The present invention provides for methods and compositions for treating, reducing and/or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, prodrug thereof, functional analog or a pharmaceutically effective salt thereof in an amount sufficient to increase activity of at least one kinase in heart tissue of the subject.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: April 24, 2018
    Assignee: DUKE UNIVERSITY
    Inventors: Kenneth W. Lyles, Cathleen S. Colon-Emeric, Christopher M. O'Connor, Dennis Abraham, Kent Nilsson, Howard Rockman, Graham Russell
  • BISPHOSPHONATE COMPOSITIONS AND METHODS FOR TREATING AND\OR REDUCING CARDIAC DYSFUNCTION
    Publication number: 20140296166
    Abstract: The present invention provides for methods and compositions for treating, reducing and/or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, prodrug thereof, functional analogue or a pharmaceutically effective salt thereof in an amount sufficient to increase activity of at least one kinase in heart tissue of the subject.
    Type: Application
    Filed: November 14, 2012
    Publication date: October 2, 2014
    Inventors: Kenneth W. Lyles, Cathleen S. Colon-Emeric, Christopher M. O'Connor, Dennis Abraham, Kent Nilson, Howard Rockman, Graham Russell
  • Method of protecting against heart failure
    Publication number: 20110288149
    Abstract: The present invention relates, in general, to heart failure, and, in particular to a method of reducing the risk of heart failure, particularly in patents with established cardiomyopathy.
    Type: Application
    Filed: May 2, 2011
    Publication date: November 24, 2011
    Inventors: Douglas A. Marchuk, Howard A. Rockman, Ferrin C. Wheeler
  • INHIBITING GSNOR
    Publication number: 20100286174
    Abstract: Treatment of myocardial infarction to reduce infarct size and organogenesis is provided by administration of agents selected from the group consisting of
    Type: Application
    Filed: May 18, 2010
    Publication date: November 11, 2010
    Applicant: Duke University
    Inventors: Jonathan S. Stamler, Howard A. Rockman
  • Use of exogenous ?-adrenergic receptor and ?-adrenergic receptor kinase gene constructs to enhance myocardial function
    Patent number: 7060871
    Abstract: The present invention deals with gene therapy for treating chronic heart failure and other cardiac disease states which are accompanied by a reduced number or functioning of myocardial beta-adrenergic receptors (?-AR). ?-AR receptor function is augmented in transgenic animals by delivery and expression of a beta-2-adrenergic receptor gene or a gene encoding a beta adrenergic receptor kinase inhibitor, resulting in increased in vivo left ventricular function. The present invention includes recombinant plasmid vectors, alternative beta-adrenergic receptor gene delivery strategies, and transgenic mice carrying a ?-AR transgene, a ?-ARK transgene, or a ?-ARK inhibitor transgene.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: June 13, 2006
    Assignee: Duke University
    Inventors: Walter J. Koch, Robert J. Lefkowitz, Carmelo A. Milano, Howard A. Rockman
  • Phosphoinositide 3-kinase mediated inhibition of GPCRs
    Publication number: 20060026702
    Abstract: The present invention relates to compounds that alter GPCR internalization and new methods for their identification. Compounds of this invention include modified phosphoinositide 3-kinase (PI3K), modified HEAT domain, modified ?-adrenergic receptor kinase 1 (?ARK1), as well as other peptides or small molecules that alter GPCR internalization. The present invention also includes the use of such compounds to treat GPCR-related diseases, such as cardiovascular disease, heart failure, asthma, nephrogenic diabetes insipidus, or hypertension.
    Type: Application
    Filed: July 30, 2004
    Publication date: February 2, 2006
    Applicant: DUKE UNIVERSITY
    Inventors: Howard Rockman, Sathyamangla Naga Prasad, Stephane Laporte, Larry Barak, Marc Caron
  • Phosphoinositide 3-kinase mediated inhibition of GPCRs
    Publication number: 20030182669
    Abstract: The present invention relates to compounds that alter GPCR internalization and new methods for their identification. Compounds of this invention include modified phosphoinositide 3-kinase (PI3K), modified HEAT domain, modified &bgr;-adrenergic receptor kinase 1 (&bgr;ARK1), as well as other peptides or small molecules that alter GPCR internalization. The present invention also includes the use of such compounds to treat GPCR-related diseases, such as cardiovascular disease, heart failure, asthma, nephrogenic diabetes insipidus, or hypertension.
    Type: Application
    Filed: March 19, 2002
    Publication date: September 25, 2003
    Inventors: Howard A. Rockman, Sathyamangla V. Naga Prasad, Stephane A. Laporte, Larry S. Barak, Marc G. Caron
  • Intracellular inhibitors of Gq protein signaling
    Patent number: 6610532
    Abstract: The present invention relates, in general, to myocardial hypertrophy and, in particular, to agents that inhibit cardiac Gq-coupled receptor signaling and to methods of inhibiting myocardial hypertrophy using same.
    Type: Grant
    Filed: July 24, 1998
    Date of Patent: August 26, 2003
    Assignee: Duke University
    Inventors: Walter J. Koch, Robert J. Lefkowitz, Shahab A. Akhter, Louis M. Luttrell, Howard Rockman
  • Use of exogenous beta-adrenergic receptor and beta-adrenergic receptor kinase gene constructs to enhance myocardial function
    Publication number: 20030026784
    Abstract: The present invention deals with gene therapy for treating chronic heart failure and other cardiac disease states which are accompanied by a reduced number or functioning of myocardial beta-adrenergic receptors (&bgr;-AR). &bgr;-AR receptor function is augmented in transgenic animals by delivery and expression of a beta-2-adrenergic receptor gene or a gene encoding a beta adrenergic receptor kinase inhibitor, resulting in increased in vivo left ventricular function. The present invention includes recombinant plasmid vectors, alternative beta-adrenergic receptor gene delivery strategies, and transgenic mice carrying a &bgr;-AR transgene, a &bgr;-ARK transgene, or a &bgr;-ARK inhibitor transgene.
    Type: Application
    Filed: June 28, 2002
    Publication date: February 6, 2003
    Applicant: DUKE UNIVERSITY
    Inventors: Walter J. Koch, Robert J. Lefkowitz, Carmelo A. Milano, Howard A. Rockman
  • Intracellular inhibitors of Gq protein signaling
    Publication number: 20020198151
    Abstract: The present invention relates, in general, to myocardial hypertrophy and, in particular, to agents that inhibit cardiac Gq-coupled receptor signaling and to methods of inhibiting myocardial hypertrophy using same.
    Type: Application
    Filed: July 12, 2002
    Publication date: December 26, 2002
    Applicant: DUKE UNIVERSITY
    Inventors: Walter J. Koch, Robert J. Lefkowitz, Shahab A. Akhter, Louis M. Luttrell, Howard A. Rockman